BrainAurora Medical Technology Limited AI Stock Analysis
Want to see HK:6681 full AI Analyst Report?
BrainAurora Medical Technology Limited (6681) AI Stock Analysis
BrainAurora Medical Technology Limited
(HKEX:6681)
The score is primarily constrained by substantial losses, persistent cash burn, and high leverage. Moderate technical momentum provides some support, but the negative P/E and lack of profitability keep the overall score low.
BrainAurora Medical Technology Limited (6681) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.86B
- Dividend Yield
- ―
- Average Volume (3M)
- 102.64M
- Price to Earnings (P/E)
- -4.8
- Beta (1Y)
- 0.84
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 165
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
BrainAurora Medical Technology Limited Business Overview & Revenue Model
Company Description
BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evalua...
BrainAurora Medical Technology Limited Financial Statement Overview
Summary
Revenue growth is strong, but severe operating losses, deeply negative cash flow, high leverage, and thin equity place financial performance at the minimum score.
Income Statement
25NegativeBalance Sheet
15Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 239.86M | 220.05M | 122.31M | 67.20M | 11.29M | 2.30M |
| Gross Profit | 103.21M | 89.45M | 54.01M | 32.06M | 3.30M | 1.30M |
| EBITDA | -256.54M | -264.78M | -149.39M | -317.63M | -470.81M | -689.82M |
| Net Income | -322.47M | -314.86M | -198.28M | -359.08M | -502.45M | -697.84M |
Balance Sheet | ||||||
| Total Assets | 1.05B | 733.20M | 599.50M | 394.85M | 418.09M | 371.30M |
| Cash, Cash Equivalents and Short-Term Investments | 658.44M | 531.78M | 343.88M | 57.58M | 287.22M | 323.74M |
| Total Debt | 556.24M | 565.76M | 388.28M | 364.07M | 328.14M | 308.76M |
| Total Liabilities | 629.79M | 637.69M | 1.06B | 727.03M | 1.51B | 1.05B |
| Stockholders Equity | 419.32M | 97.39M | -463.65M | -332.14M | -1.09B | -681.28M |
Cash Flow | ||||||
| Free Cash Flow | -74.67M | -205.75M | -167.24M | -155.00M | -119.74M | -60.31M |
| Operating Cash Flow | -67.88M | -178.03M | -149.49M | -136.87M | -100.68M | -49.21M |
| Investing Cash Flow | -105.33M | -272.88M | 125.37M | 102.55M | -334.46M | -21.48M |
| Financing Cash Flow | 116.19M | 339.27M | 315.50M | 63.53M | 139.65M | 393.61M |
BrainAurora Medical Technology Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6681, the sentiment is Neutral. The current price of 1.37 is above the 20-day moving average (MA) of 1.26, above the 50-day MA of 1.20, and below the 200-day MA of 2.65, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 53.21 is Neutral, neither overbought nor oversold. The STOCH value of 47.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6681.
BrainAurora Medical Technology Limited Peers Comparison
Overall Rating
HK:152166Neutral
HK:334755Neutral
HK:215753Neutral
HK:668144Neutral
HK:147743Neutral
HK:662240Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | HKD 4.23B | 50.74 | 3.02% | ― | 10.32% | 178.23% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | HKD 40.89B | -99.75 | -2.00% | 0.39% | 21.72% | -169.67% | |
| 53Neutral | HKD 4.87B | 17.00 | 17.36% | ― | 46.90% | ― | |
| 44Neutral | HKD 1.86B | -4.75 | -124.83% | ― | ― | ― | |
| 43Neutral | HKD 4.06B | -27.56 | -3.44% | ― | 77.55% | 50.34% | |
| 40Underperform | HKD 1.19B | -4.86 | -14.41% | ― | 2.56% | 20.20% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6681 | BrainAurora Medical Technology Limited | 1.37 | -5.10 | -78.83% | |
| HK:3347 | Hangzhou Tigermed Consulting Co., Ltd. Class H | 36.82 | -4.23 | -10.30% | |
| HK:1477 | Ocumension Therapeutics | 4.97 | -3.59 | -41.88% | |
| HK:1521 | Frontage Holdings Corp. | 2.08 | 1.01 | 93.93% | |
| HK:2157 | Lepu Biopharma Co. Ltd. Class H | 2.70 | -3.31 | -55.07% | |
| HK:6622 | Zhaoke Ophthalmology Ltd. | 2.17 | -1.31 | -37.64% |
BrainAurora Medical Technology Limited Corporate Events
BrainAurora Wins First Beijing Approval for Depression Cognitive Assessment Device
BrainAurora Medical Technology has received a Class II Medical Device Registration Certificate from the Beijing Municipal Medical Products Administration for its standalone cognitive function assessment software for patients with depression. The prod...
BrainAurora defines optimal pediatric doses for cognitive digital therapeutics in major BMC Medicine study
BrainAurora Medical Technology has reported the publication of a major study in BMC Medicine that defines optimal digital training doses for children and adolescents with cognitive impairments using its Brain Function Information Management Platform....
BrainAurora’s Self-Adaptive Digital Therapy Shows Strong Schizophrenia Results
BrainAurora Medical Technology Limited has reported new clinical research results demonstrating the efficacy of its self-adaptive computerized cognitive remediation technology for schizophrenia. The study used the company’s Brain Function Information...
BrainAurora lifts revenue as it deepens push into AI cognitive digital therapeutics
BrainAurora Medical Technology Limited reported interim revenue of RMB119.9 million for the six months ended June 30, 2026, up 19.8% year on year, while its loss widened modestly, with total comprehensive expense at RMB134.6 million and an adjusted n...
BrainAurora Schedules Board Meeting to Approve Interim 2026 Results
BrainAurora Medical Technology Limited, a listed medical technology company incorporated in the Cayman Islands and traded on the Hong Kong Stock Exchange, operates through a group structure focused on healthcare innovation and related services. Its g...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
